{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:39:03Z","timestamp":1791052743282,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4466-7","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T12:25:10Z","timestamp":1525782310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE)"],"prefix":"10.1186","volume":"18","author":[{"given":"Chang Woo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Mo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ik Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Jin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Cheol","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Beom","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Noe","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Kyu","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hyuk","family":"Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyung Mo","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Suk","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-8354","authenticated-orcid":false,"given":"Suk-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"issue":"17","key":"4466_CR1","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731\u201340.","journal-title":"N Engl J Med"},{"issue":"5","key":"4466_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1097\/01.sla.0000161980.46459.96","volume":"241","author":"JG Guillem","year":"2005","unstructured":"Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, Paty PB, Weiser MR, Klimstra D, Saltz L, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241(5):829\u201336. discussion 836-828","journal-title":"Ann Surg"},{"issue":"10","key":"4466_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/bjs.1800691019","volume":"69","author":"RJ Heald","year":"1982","unstructured":"Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? Br J Surg. 1982;69(10):613\u20136.","journal-title":"Br J Surg"},{"issue":"9","key":"4466_CR4","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1056\/NEJMoa010580","volume":"345","author":"E Kapiteijn","year":"2001","unstructured":"Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345(9):638\u201346.","journal-title":"N Engl J Med"},{"issue":"11","key":"4466_CR5","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"355","author":"JF Bosset","year":"2006","unstructured":"Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114\u201323.","journal-title":"N Engl J Med"},{"issue":"28","key":"4466_CR6","doi-asserted-by":"publisher","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","volume":"24","author":"JP Gerard","year":"2006","unstructured":"Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620\u20135.","journal-title":"J Clin Oncol"},{"issue":"16","key":"4466_CR7","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","volume":"30","author":"R Sauer","year":"2012","unstructured":"Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926\u201333.","journal-title":"J Clin Oncol"},{"issue":"31","key":"4466_CR8","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1200\/JCO.2009.22.0467","volume":"27","author":"MS Roh","year":"2009","unstructured":"Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27(31):5124\u201330.","journal-title":"J Clin Oncol"},{"issue":"34","key":"4466_CR9","doi-asserted-by":"publisher","first-page":"8688","DOI":"10.1200\/JCO.2005.02.1329","volume":"23","author":"C Rodel","year":"2005","unstructured":"Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23(34):8688\u201396.","journal-title":"J Clin Oncol"},{"key":"4466_CR10","doi-asserted-by":"crossref","unstructured":"Garcia-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD, Rothenberger DA: A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon rectum 2003, 46(3):298-304.","DOI":"10.1007\/s10350-004-6545-x"},{"issue":"8","key":"4466_CR11","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1200\/JCO.1999.17.8.2396","volume":"17","author":"Y Francois","year":"1999","unstructured":"Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, Souquet JC, Adeleine P, Gerard JP. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17(8):2396.","journal-title":"J Clin Oncol"},{"issue":"10","key":"4466_CR12","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1245\/s10434-008-9892-3","volume":"15","author":"H Tulchinsky","year":"2008","unstructured":"Tulchinsky H, Shmueli E, Figer A, Klausner JM, Rabau M. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol. 2008;15(10):2661\u20137.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"4466_CR13","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/SLA.0b013e3181b91e63","volume":"250","author":"MF Kalady","year":"2009","unstructured":"Kalady MF, de Campos-Lobato LF, Stocchi L, Geisler DP, Dietz D, Lavery IC, Fazio VW. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250(4):582\u20139.","journal-title":"Ann Surg"},{"key":"4466_CR14","doi-asserted-by":"crossref","unstructured":"de Campos-Lobato LF, Geisler DP, da Luz Moreira A, Stocchi L, Dietz D, Kalady MF: Neoadjuvant therapy for rectal cancer: the impact of longer interval between chemoradiation and surgery. J Gastrointest Surg 2011, 15(3):444-450.","DOI":"10.1007\/s11605-010-1197-8"},{"issue":"7","key":"4466_CR15","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/bjs.9112","volume":"100","author":"DA Sloothaak","year":"2013","unstructured":"Sloothaak DA, Geijsen DE, van Leersum NJ, Punt CJ, Buskens CJ, Bemelman WA, Tanis PJ. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2013;100(7):933\u20139.","journal-title":"Br J Surg"},{"issue":"10","key":"4466_CR16","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","volume":"28","author":"JP Gerard","year":"2010","unstructured":"Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, Francois E, de La Roche G, Bouche O, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12\/0405-Prodige 2. J Clin Oncol. 2010;28(10):1638\u201344.","journal-title":"J Clin Oncol"},{"issue":"20","key":"4466_CR17","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1200\/JCO.2010.34.4911","volume":"29","author":"C Aschele","year":"2011","unstructured":"Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29(20):2773\u201380.","journal-title":"J Clin Oncol"},{"issue":"36","key":"4466_CR18","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1200\/JCO.2012.42.8771","volume":"30","author":"JP Gerard","year":"2012","unstructured":"Gerard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, Vendrely V, Francois E, de La Roche G, Bouche O, et al. Clinical outcome of the ACCORD 12\/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30(36):4558\u201365.","journal-title":"J Clin Oncol"},{"issue":"18","key":"4466_CR19","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1200\/JCO.2008.21.1771","volume":"27","author":"CG Willett","year":"2009","unstructured":"Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27(18):3020\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4466_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijrobp.2010.08.005","volume":"82","author":"T Dipetrillo","year":"2012","unstructured":"Dipetrillo T, Pricolo V, Lagares-Garcia J, Vrees M, Klipfel A, Cataldo T, Sikov W, McNulty B, Shipley J, Anderson E, et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82(1):124\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4466_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/SLA.0b013e3182196e1f","volume":"254","author":"J Garcia-Aguilar","year":"2011","unstructured":"Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM. Timing of rectal Cancer response to Chemoradiation C: optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg. 2011;254(1):97\u2013102.","journal-title":"Ann Surg"},{"issue":"5","key":"4466_CR22","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.ijrobp.2014.07.021","volume":"90","author":"YH Gao","year":"2014","unstructured":"Gao YH, Lin JZ, An X, Luo JL, Cai MY, Cai PQ, Kong LH, Liu GC, Tang JH, Chen G, et al. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial. Int J Radiat Oncol Biol Phys. 2014;90(5):1153\u201360.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"4466_CR23","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1470-2045(15)00004-2","volume":"16","author":"J Garcia-Aguilar","year":"2015","unstructured":"Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, Kumar AS, Oommen S, Coutsoftides T, Hunt SR, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16(8):957\u201366.","journal-title":"Lancet Oncol"},{"key":"4466_CR24","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1186\/s12885-015-1632-z","volume":"15","author":"JJ Smith","year":"2015","unstructured":"Smith JJ, Chow OS, Gollub MJ, Nash GM, Temple LK, Weiser MR, Guillem JG, Paty PB, Avila K, Garcia-Aguilar J. Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer. 2015;15:767.","journal-title":"BMC Cancer"},{"issue":"1","key":"4466_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00280-015-2763-2","volume":"76","author":"J Xiao","year":"2015","unstructured":"Xiao J, Chen Z, Li W, Yang Z, Huang Y, Zheng J, Deng Y, Wang L, Ren D, Peng J, et al. Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial. Cancer Chemother Pharmacol. 2015;76(1):21\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4466_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00595-015-1218-z","volume":"46","author":"K Uehara","year":"2016","unstructured":"Uehara K, Nagino M. Neoadjuvant treatment for locally advanced rectal cancer: a systematic review. Surg Today. 2016;46(2):161\u20138.","journal-title":"Surg Today"},{"issue":"1","key":"4466_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/1097-0142(19950101)75:1<11::AID-CNCR2820750104>3.0.CO;2-N","volume":"75","author":"BN Stein","year":"1995","unstructured":"Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer. 1995;75(1):11\u20137.","journal-title":"Cancer"},{"issue":"8","key":"4466_CR28","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1200\/JCO.1999.17.8.2412","volume":"17","author":"RA Popescu","year":"1999","unstructured":"Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 1999;17(8):2412\u20138.","journal-title":"J Clin Oncol"},{"issue":"28","key":"4466_CR29","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","volume":"29","author":"G Yothers","year":"2011","unstructured":"Yothers G, O'Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768\u201374.","journal-title":"J Clin Oncol"},{"issue":"7","key":"4466_CR30","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1200\/JCO.2002.07.010","volume":"20","author":"ID Nagtegaal","year":"2002","unstructured":"Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken JH. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol. 2002;20(7):1729\u201334.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4466_CR31","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","volume":"73","author":"AM Mandard","year":"1994","unstructured":"Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680\u20136.","journal-title":"Cancer"},{"issue":"1","key":"4466_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s003840050072","volume":"12","author":"O Dworak","year":"1997","unstructured":"Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Color Dis. 1997;12(1):19\u201323.","journal-title":"Int J Color Dis"},{"issue":"2","key":"4466_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg"},{"key":"4466_CR34","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) [ https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_40 ]. Accessed 3 Apr 2018."},{"issue":"11","key":"4466_CR35","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S1470-2045(14)70377-8","volume":"15","author":"YS Hong","year":"2014","unstructured":"Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014;15(11):1245\u201353.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4466_CR36","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S1470-2045(15)00159-X","volume":"16","author":"C Rodel","year":"2015","unstructured":"Rodel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO\/ARO\/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979\u201389.","journal-title":"Lancet Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4466-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-4466-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4466-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T19:15:46Z","timestamp":1661195746000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4466-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4466"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4466-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"21 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors follow either the Declaration of Helsinki to protect the patients, and the trial will be performed according to the ICH-GCP guidelines. The institutional review board of the principal investigator (S-H Lee) approved the trial (KHNMC 2016-04-042-001) at Kyung Hee University Hospital at Gangdong. Moreover, the full lists of ethics committees that approved the trial are as follows: IRB 2016-106 at Chuncheon Sacred Heart Hospital, CR316102 at Wonju Severance Christian Hospital, IRB 2016-11-015 at Chungnam National University Hospital, IRB 2017-02-053 at Kyung Hee Medical Center, WKUH 2017-02-008-001 at Wonkwang University Hospital, IRB 16-0242 at Inje University Busan Paik Hospital, SGPAIK 2016-09-001-004 at Inje University Sanggye Paik Hospital, DSMC 2016-09-022-001 at Keimyung University Dongsan Medical Center, IRB 3-2017-0019 at Gangnam Severance Hospital, IRB 05-2016-179 at Pusan National University Yangsan Hospital, IRB 2017-4239-0001 at Seoul St. Mary\u2019s Hospital. All patients will understand and agree to the aims and process of the trial, possible results and risks. An informed consent has to be written in the language which patients can understand, and be explained by an investigator. If patients cannot read an informed consent, an investigator has to read it in the presence of a witness. Although a patient signed an informed consent at first, an investigator has to stop a process of the patient when he or she refuses. A copy of signed informed consent should be provided to the patient. An original copy will be an investigator\u2019s safekeeping.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"538"}}